James D. Lewis
University of Pennsylvania
Internal medicineSurgeryOdds ratioRetrospective cohort studyCohort studyImmunologyHazard ratioInflammatory bowel diseaseDiseaseCrohn's diseaseUlcerative colitisPopulationIn patientIncidence (epidemiology)Confidence intervalColorectal cancerMedicineCohortBiologyGastroenterology
634Publications
108H-index
32.1kCitations
Publications 636
Newest
#1Benoit Chassaing (University of Paris)H-Index: 3
#2Charlene Compher (UPenn: University of Pennsylvania)H-Index: 46
Last. James D. Lewis (UPenn: University of Pennsylvania)H-Index: 108
view all 21 authors...
Abstract null Background & Aims null Epidemiologic and murine studies suggest that dietary emulsifiers promote development of diseases associated with microbiota dysbiosis. While the detrimental impact of these compounds on the intestinal microbiota and intestinal health have been demonstrated in animal and in vitro models, impact of these food additives in healthy humans remains poorly characterized. null Methods null To examine this notion in humans, we performed a double-blind controlled-feed...
Source
Source
Source
#1Frank I. Scott (Anschutz Medical Campus)H-Index: 18
#2Amneet K. Hans (Emory University)H-Index: 3
Last. James D. Lewis (UPenn: University of Pennsylvania)H-Index: 108
view all 7 authors...
Abstract : Background & Aims Ustekinumab is a monoclonal antibody against interleukin 12 and interleukin 23 that has been approved by the Food and Drug Administration for treatment of Crohn’s disease (CD). We sought to identify the ideal position for ustekinumab in treatment algorithms for CD. Methods We constructed a Markov model to identify an optimal treatment sequence for CD that included ustekinumab for 1 year or more. The base case was a 35-year old male with moderate to severe CD who had ...
Source
Source
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 184
#2James D. Lewis (UPenn: University of Pennsylvania)H-Index: 108
Last. Brian G. FeaganH-Index: 116
view all 10 authors...
Background and aims null Patient-reported outcomes are recommended endpoints in Crohn's disease (CD) trials. The association between patient-reported general well-being relative to symptoms of diarrhea and abdominal pain (AP) in patients with moderate-to-severe CD was explored. null Methods null Patients from 3 randomized, placebo-controlled, double-blind adalimumab or upadacitinib studies with average daily very soft/liquid stool frequency (SF) ≥4 and/or AP score ≥2 at baseline were included. U...
Source
#1Ravy K. VajraveluH-Index: 10
#2Jordan Shapiro (BCM: Baylor College of Medicine)H-Index: 2
Last. Hashem B. El-Serag (Michael E. DeBakey Veterans Affairs Medical Center in Houston)H-Index: 124
view all 6 authors...
Background & Aims null Laboratory studies have demonstrated that antibiotic use in conjunction with bowel purgatives causes alterations to the gut microbiota. Because gut microbiota changes may be a trigger for the development of irritable bowel syndrome (IBS), we sought to assess whether individuals who undergo bowel cleansing for colonoscopy and have concurrent antibiotic exposure develop IBS at higher rates than individuals who undergo colonoscopy without antibiotic exposure. null null null M...
Source
#1James D. LewisH-Index: 108
#2Robert S. SandlerH-Index: 104
Last. John F. ValentineH-Index: 46
view all 30 authors...
#1James D. Lewis (UPenn: University of Pennsylvania)H-Index: 108
#2Robert S. Sandler (UNC: University of North Carolina at Chapel Hill)H-Index: 104
Last. Hans H Herfarth (UNC: University of North Carolina at Chapel Hill)H-Index: 69
view all 31 authors...
Abstract Background & Aims This study compared the effectiveness of the Specific Carbohydrate Diet (SCD) to the Mediterranean Diet (MD) as treatment for Crohn's disease (CD) with mild to moderate symptoms. Methods Adult patients with CD and with mild-moderate symptoms were randomly assigned 1:1 to consume the MD or SCD for 12 weeks. For the first 6-weeks, participants received prepared meals and snacks according to their assigned diet. After 6-weeks, participants were instructed to follow the di...
Source
#1Laura E. Raffals (Mayo Clinic)H-Index: 23
#2Sumona Saha (UW: University of Wisconsin-Madison)H-Index: 14
Last. Alandra WeaverH-Index: 5
view all 31 authors...
Background null Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples. null Methods null We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized dat...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.